ライフサイエンスコーパス: adenosine diphosphate

1 eotides (particularly adenosine triphosphate/adenosine diphosphate).

2 specifically binds guanosine diphosphate and adenosine diphosphate.

3 sue injury and sensitization of platelets to adenosine diphosphate.

4 secretion induced by thrombin, collagen, and adenosine diphosphate.

5 needed to undock the neck linker and release adenosine diphosphate.

6 on and higher ex vivo platelet reactivity to adenosine diphosphate.

7 ctivated receptor (PAR) agonists, but not by adenosine diphosphate.

8 hosphorylation to adenosine triphosphate and adenosine diphosphate.

9 ntly as (3)H-adenosine triphosphate and (3)H-adenosine diphosphate.

10 when aggregation was induced by 5 mumol/l of adenosine diphosphate.

11 d in complex with a pair of products TPP and adenosine diphosphate.

12 oms resolution in complex with magnesium and adenosine diphosphate.

13 tance aggregometry in response to 20 mumol/L adenosine diphosphate.

14 cell fluorescence similar to that induced by adenosine diphosphate (10 muM) or thrombin (1 U/mL).

15 light transmittance aggregometry responses (adenosine diphosphate 20 muM) post-maintenance dose were

16 ers were defined by a relative inhibition of adenosine diphosphate (20 micromol/L)-induced platelet a

17 onstrated impaired microvessel relaxation to adenosine diphosphate (29+/-3% versus 61+/-6%, CHOL vers

18 ts [PRU]), light transmittance aggregometry (adenosine diphosphate 5 and 20 mumol/l and arachidonic a

19 Light transmittance aggregometry (adenosine diphosphate 5 to 20 muM), VerifyNow P2Y12, and

20 mbranes but is recruited to molecularly aged adenosine diphosphate actin filaments and is necessary f

21 of tissue injury and sensitized platelets to adenosine diphosphate activation.

22 Nucleotide (ATP, adenosine diphosphate, adenosine monophosphate) and nucl

23 termined after incubation with ATP (5 mM) or adenosine diphosphate (ADP) (5 mM) with or without 15 mi

24 ed greater platelet aggregation to 5-mumol/l adenosine diphosphate (ADP) (50.7 +/- 16.4% vs. 34.2 +/-

25 not reflected in corresponding increases in adenosine diphosphate (ADP) and adenosine monophosphate

26 osine triphosphate (ATP) and its precursors, adenosine diphosphate (ADP) and adenosine monophosphate

27 esponses stimulated by weak agonists such as adenosine diphosphate (ADP) and adrenaline were severely

28 tivity by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA).

29 Light transmittance aggregation induced by adenosine diphosphate (ADP) and arachidonic acid, total

30 Platelet aggregation after adenosine diphosphate (ADP) and collagen stimuli were as

31 g PI3Kgamma disaggregated following low-dose adenosine diphosphate (ADP) and had a mildly impaired ab

32 MRS showed trends for more rapid calculated adenosine diphosphate (ADP) and phosphocreatine (PCr) re

33 Adhesion occurs more slowly than with adenosine diphosphate (ADP) and requires phosphatidylino

34 n or CRP, whereas they aggregate normally to adenosine diphosphate (ADP) and spread on fibrinogen.

35 b was measured with and without low and high adenosine diphosphate (ADP) and thrombin receptor activa

36 ce of low levels of primary agonists such as adenosine diphosphate (ADP) and thrombin, or others like

37 of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increase

38 We measured platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggre

39 Only in adenosine diphosphate (ADP) can the mutant catalytically

40 Adenosine diphosphate (ADP) enhances platelet activation

41 pendence of the adenosine triphosphate (ATP)/adenosine diphosphate (ADP) exchange rates of F(1)-ATPas

42 Adenosine diphosphate (ADP) is known to have interesting

43 ownregulate the adenosine triphosphate (ATP)/adenosine diphosphate (ADP) metabolite ratio which stron

44 exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk f

45 high-resolution structure revealed that the adenosine diphosphate (ADP) moiety of the FAD prosthetic

46 effect of adenosine monophosphate (AMP) and adenosine diphosphate (ADP) on flagellar beating is not

47 ng to alphaIIbbeta3 following stimulation by adenosine diphosphate (ADP) or protease-activated recept

48 venous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might r

49 n-coupled nucleotide receptors: the platelet adenosine diphosphate (ADP) receptor coupled to stimulat

50 The adenosine diphosphate (ADP) receptor P2RY12 (purinergic

51 abolite that inhibits the platelet P2Y(1)(2) adenosine diphosphate (ADP) receptor, decreasing platele

52 wn regulator that operates downstream of the adenosine diphosphate (ADP) receptor, P2Y12, a target of

53 m in thrombus formation: the coinhibition of adenosine diphosphate (ADP) receptors with collagen rece

54 ht chain (RLC) phosphorylation and strain on adenosine diphosphate (ADP) release from cross-bridges i

55 We identify EspJ as a unique adenosine diphosphate (ADP) ribosyltransferase that dire

56 Activation of human platelets with adenosine diphosphate (ADP) stimulated the release of VE

57 Structures in the presence or absence of adenosine diphosphate (ADP) suggest that motions of the

58 g either 2), inorganic phosphate (Pi) or 3), adenosine diphosphate (ADP) to the motility solutions.

59 lonyl-CoA, adenosine triphosphate (ATP), and adenosine diphosphate (ADP) were separated by capillary

60 ic rats to eNOS-dependent (acetylcholine and adenosine diphosphate (ADP)) and -independent (nitroglyc

61 sphate (ATP) and its first five catabolites: adenosine diphosphate (ADP), adenosine monophosphate (AM

62 Adenosine diphosphate (ADP), adenosine triphosphate (ATP

63 ergy including adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate

64 vity assay, measuring platelet reactivity to adenosine diphosphate (ADP), convulxin (CVX), and thromb

65 early GPIb-IX signaling independent of Syk, adenosine diphosphate (ADP), or thromboxane A2 (TXA2), i

66 ity towards ATP and is strongly inhibited by adenosine diphosphate (ADP), we asked how Hsp104 functio

67 elet homeostasis and allow responsiveness to adenosine diphosphate (ADP), we developed a computationa

68 tructural ensembles for p47-p97 complexes in adenosine diphosphate (ADP)- and adenosine triphosphate

69 enzeneacetamide methanesulfonate), inhibited adenosine diphosphate (ADP)-, 2-methylthioADP (2-MeSADP)

70 omain, 12F1 and 6F1, bound preferentially to adenosine diphosphate (ADP)-activated platelets.

71 ity for Tim44, as well as through release of adenosine diphosphate (ADP)-bound mtHsp70 from Tim44 by

72 to demonstrate that ATP-bound Rok1, but not adenosine diphosphate (ADP)-bound Rok1, stabilizes Rrp5

73 electron microscopy (cryo-EM) structures for adenosine diphosphate (ADP)-bound, full-length, hexameri

74 utaneous coronary intervention by inhibiting adenosine diphosphate (ADP)-dependent platelet activatio

75 analyzer-ASA score > or = 550, 5 micromol/l adenosine diphosphate (ADP)-induced aggregation > or = 7

76 Adenosine diphosphate (ADP)-induced platelet reactivity

77 Adenosine diphosphate (ADP)-mediated platelet aggregatio

78 We show that the adenosine diphosphate (ADP)-reactive purinergic (P2Y12)

79 Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that act

80 he rapid and robust synthesis of polymers of adenosine diphosphate (ADP)-ribose (PAR) chains, primari

81 he MERS-CoV macro domain as a more efficient adenosine diphosphate (ADP)-ribose binding module than m

82 e find that puffs acquire elevated levels of adenosine diphosphate (ADP)-ribose modified proteins and

83 The poly(adenosine diphosphate (ADP)-ribose) polymerase (PARP) pr

84 e that SIRT6 physically associates with poly[adenosine diphosphate (ADP)-ribose] polymerase 1 (PARP1)

85 Poly[adenosine diphosphate (ADP)-ribose] polymerases (PARPs)

86 with ER stress, we found elevated levels of adenosine diphosphate (ADP)-ribosylated BiP in the inact

87 Poly adenosine diphosphate (ADP)-ribosylation (PARylation) by

88 io]triphosphate (GTP gamma S) stimulation of adenosine diphosphate (ADP)-ribosylation factor (ARF) an

89 Protein adenosine diphosphate (ADP)-ribosylation is a physiologi

90 Adenosine diphosphate (ADP)-ribosylation is a post-trans

91 c translation elongation factor 2 (eEF2) via adenosine diphosphate (ADP)-ribosylation of a modified h

92 The key event is adenosine diphosphate (ADP)-ribosylation of the human si

93 denosine antibodies were used to detect ecto-adenosine diphosphate (ADP)-ribosyltransferase (ART) act

94 An adenosine diphosphate (ADP)-ribosyltransferase that caus

95 The adenosine diphosphate (ADP)-stimulated platelet aggregat

96 The primary outcome measure was adenosine diphosphate (ADP)-stimulated platelet fibrinog

97 ia also cause changes in the ratio of ATP to adenosine diphosphate (ADP).

98 rombogenic coagonists including collagen and adenosine diphosphate (ADP).

99 esin-1, causing tubulin-activated release of adenosine diphosphate (ADP).

100 nosine triphosphate (ATP) or activation with adenosine diphosphate (ADP).

101 othelium, and in vitro following exposure to adenosine diphosphate (ADP).

102 can be overcome by the addition of exogenous adenosine diphosphate (ADP).

103 ellular AMP:adenosine triphosphate (ATP) and adenosine diphosphate (ADP):ATP ratios and balancing the

104 lease associated with main power stroke) and adenosine diphosphate (ADP, release associated with mino

105 endent signaling (e.g., by sirtuins and poly-adenosine diphosphate [ADP] ribose polymerases [PARPs])

106 sed using agonists specific (6 and 20 microM adenosine diphosphate [ADP]) and nonspecific (6 microg/m

107 f p21, caspase cascade activation, and poly (adenosine diphosphate [ADP]) ribose (PARP) cleavage.

108 Platelet aggregation (5 and 20 muM adenosine diphosphate [ADP]), ADP-stimulated expression

109 ation, cleavage of caspase 3, and PARP (poly-adenosine diphosphate [ADP]-ribose polymerase), and incr

110 Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/

111 ith DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in

112 Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), h

113 ent study investigated the potential of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP-1)

114 ional DDB2 and involved the activity of poly(adenosine diphosphate [ADP]-ribose) polymerase 1.

115 tion by pan-caspase inhibitor abolished poly(adenosine diphosphate [ADP]-ribose) polymerase cleavage

116 on of caspases-8 and -3 and cleavage of poly(adenosine diphosphate [ADP]-ribose) polymerase following

117 Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor

118 positive staining for nitrotyrosine and poly(adenosine diphosphate [ADP]-ribose) polymerase-1 (PARP-1

119 uent cleavage of the DNA repair enzyme poly (adenosine diphosphate [ADP]-ribose) polymerase.

120 The nuclear enzyme poly(adenosine diphosphate [ADP]-ribose) synthase (PARS) is a

121 se-9 and -3 activation, and cleavage of poly(adenosine diphosphate [ADP]-ribose)polymerase.

122 etic cofactors (adenosine triphosphate [ATP]/adenosine diphosphate [ADP]/adenosine monophosphate [AMP

123 We have used adenosine diphosphate analogs containing electron parama

124 lephrine group with significant increases in adenosine diphosphate and adenosine monophosphate and no

125 lets responded in a dose-dependent manner to adenosine diphosphate and protease-activating peptide (P

126 trapped not ATP, but the reaction products, adenosine diphosphate and the phosphorylated RIIbeta sub

127 els of platelet reactivity were similar with adenosine diphosphate and thrombin.

128 /-) blood, even in the presence of exogenous adenosine diphosphate and thromboxane A(2).

129 d with variation in the platelet response to adenosine diphosphate and/or the collagen-mimetic peptid

130 Soluble apyrase reduced renal ATP, adenosine diphosphate, and adenosine monophosphate, but

131 structure of MsbA in complex with magnesium, adenosine diphosphate, and inorganic vanadate (Mg.ADP.Vi

132 owing stimuli to arachidonic acid, collagen, adenosine diphosphate, and thrombin as secondary endpoin

133 mal platelet aggregation to 5 and 20 mumol/l adenosine diphosphate, and VerifyNow P2Y12 platelet resp

134 The potent intravenous adenosine diphosphate antagonist cangrelor substantially

135 In addition to anticoagulation and an adenosine diphosphate-antagonist an adjunct therapy with

136 d stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination th

137 pyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophospha

138 amma-methyleneadenosine 5'-triphosphate, and adenosine diphosphate beryllium fluoride.

139 migration of primary microglial cells toward adenosine diphosphate by 257, 247, 301, 394, and 345% fo

140 n/epinephrine agonist cartridge and collagen/adenosine diphosphate (CADP) agonist cartridge, VerifyNo

141 by platelet aggregation to arachidonic acid, adenosine diphosphate, collagen and epinephrine, Platele

142 Calculated cytosolic adenosine diphosphate concentration decreased, whereas t

143 HMW multimers and the closure time with adenosine diphosphate (CT-ADP), a point-of-care measure

144 r the addition of glutamate and malate (GM), adenosine diphosphate (d), succinate (S) and octanoyl ca

145 High on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is a we

146 ed platelet aggregation to arachidonic acid, adenosine diphosphate, epinephrine, and platelet functio

147 e redox potential and adenosine triphosphate/adenosine diphosphate failed to reach a new steady state

148 : ATP, phosphocreatine, inorganic phosphate, adenosine diphosphate, Gibbs free energy of ATP hydrolys

149 lso exhibited activity towards quercetin and adenosine diphosphate glucose (ADPG), kaempferol and UDP

150 Adenosine diphosphate glucose pyrophosphorylase (AGPase)

151 ransgenic reports point to the importance of adenosine diphosphate glucose pyrophosphorylase in contr

152 transferase (GT) that transfers glucose from adenosine diphosphate glucose to a glucan chain acceptor

153 e >> 5'adenosine-triphosphate (ATP) > or = 5'adenosine-diphosphate > 5'uridine-triphosphate > or = 5'

154 Poly(ADP-ribose) polymerase-1 (PARP-1) (ADP, adenosine diphosphate) has a modular domain architecture

155 ency, exhibit limited adenosine triphosphate/adenosine diphosphate hydrolysis activity, and fail to s

156 are lacking for PARG, the specific inhibitor adenosine diphosphate (hydroxymethyl)pyrrolidinediol (AD

157 omain is protected from dephosphorylation by adenosine diphosphate in the complete absence of the bet

158 Platelet function parameters included adenosine diphosphate-induced (20 and 5 micromol/L) maxi

159 After randomization, maximal adenosine diphosphate-induced (20 micromol/L) platelet a

160 bolished the 3-fold prolongation in collagen adenosine diphosphate-induced closure times seen in exte

161 reactivity was increased when measured using adenosine diphosphate-induced light transmission aggrego

162 telet activation, and is mediated in part by adenosine diphosphate-induced platelet activation.

163 Maximum adenosine diphosphate-induced platelet aggregation (20 m

164 Adenosine diphosphate-induced platelet aggregation was a

165 e (AppCHClppA) are competitive inhibitors of adenosine diphosphate-induced platelet aggregation, whic

166 edly lower PR at all times (5- and 20-microM adenosine diphosphate-induced, and 15- and 25-microM thr

167 pirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors.

168 creatine kinase catalyzed phosphorylation of adenosine diphosphate is examined in two independent ser

169 cteroids, thus indicating that extracellular adenosine diphosphate is important during nodulation.

170 Adenosine triphosphate/adenosine diphosphate is metabolized to adenosine throug

171 in intramuscular inorganic phosphate, H(+) , adenosine diphosphate, lactate and phosphocreatine deple

172 s converting adenosine triphosphate (ATP) to adenosine diphosphate or adenosine monophosphate.

173 let aggregation and degranulation induced by adenosine diphosphate or collagen were diminished but we

174 ns diminished channel responses to magnesium adenosine diphosphate or diazoxide, while dominant KCNJ1

175 n vitro stimulation of PT-VWD platelets with adenosine diphosphate or thrombin demonstrates a signifi

176 Collagen-, collagen-related peptide-, adenosine diphosphate-, or thrombin-induced platelet agg

177 We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an importan

178 Nicotinamide adenosine diphosphate oxidase 2 knockout was also associ

179 predicted aggregation to 2 muM and 10 muM of adenosine diphosphate (P = .02 and <.001, respectively)

180 uent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.

181 ctivity, especially with tests measuring the adenosine diphosphate-P2Y12 receptor pathway, without si

182 chondrial inner membrane, thereby uncoupling adenosine diphosphate phosphorylation from nutrient oxid

183 caspase activation and the cleavage of poly(adenosine diphosphate) (poly(ADP)) ribose polymerase.

184 in the liver, whereas adenosine triphosphate/adenosine diphosphate ratios remained low.

185 phate levels, whereas adenosine triphosphate/adenosine diphosphate ratios were low.

186 ficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidog

187 severity of the disease, early treatment of adenosine diphosphate receptor antagonists at presentati

188 rials are needed to define the role of newer adenosine diphosphate receptor antagonists in this setti

189 Prasugrel and ticagrelor, new P2Y12-adenosine diphosphate receptor antagonists, are associat

190 The P2Y12-adenosine diphosphate receptor blockade was assessed by

191 The standard adenosine diphosphate receptor blocker in this setting i

192 Ticagrelor is a direct-acting P2Y12-adenosine diphosphate receptor blocker.

193 hine blunts the antiplatelet effects of oral adenosine diphosphate receptor blockers.

194 Guidelines recommend the use of adenosine diphosphate receptor inhibitor (ADPri) therapy

195 nction testing to guide choice and dosing of adenosine diphosphate receptor inhibitor (ADPri) therapy

196 This study used data from the Treatment With Adenosine Diphosphate Receptor Inhibitors-Longitudinal A

197 2365 patients enrolled in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

198 Using TRANSLATE-ACS (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

199 d States TRANSLATE-ACS study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

200 ive from 233 hospitals in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

201 The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

202 e analogue, is an intravenous blocker of the adenosine diphosphate receptor P2Y(12).

203 cleotide exchange factor CalDAG-GEFI and the adenosine diphosphate receptor P2Y12 as independent path

204 ivation of integrin alphaIIbbeta3, while the adenosine diphosphate receptor P2Y12, the target for ant

205 Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist that in the CH

206 the availability of rapidly-acting platelet adenosine diphosphate-receptor antagonists, the need for

207 isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive

208 ribosyltransferases catalyze the transfer of adenosine diphosphate ribose (ADP-ribose) from nicotinam

209 brane protein that converts NAD primarily to adenosine diphosphate ribose (ADPR) and a small amount o

210 It metabolizes NAD(+) to adenosine diphosphate ribose (ADPR) and cyclic ADPR, reg

211 However, these enzymes also produce adenosine diphosphate ribose (ADPR) and nicotinic acid a

212 where, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide aden

213 It is activated by intracellular adenosine diphosphate ribose (ADPR) through a diphosphor

214 f two potent Ca(2+) releasing agents: cyclic adenosine diphosphate ribose (cADPR) from nicotinamide a

215 of the calcium-mobilizing metabolite, cyclic adenosine diphosphate ribose (cADPR), from nicotinamide

216 osal mast cells through an IL-13-CD38-cyclic adenosine diphosphate ribose (cADPR)-dependent process.

217 e ribose (ADPR) and a small amount of cyclic adenosine diphosphate ribose (cADPR).

218 k incorporates the signaling molecule cyclic adenosine diphosphate ribose (cADPR).

219 ates the cytosolic signaling molecule cyclic adenosine diphosphate ribose (cADPR).

220 Blockade of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine-sensitive

221 We identify a variant of cyclic adenosine diphosphate ribose as a biomarker of TIR enzym

222 ng agents sphingosine-1-phosphate and cyclic adenosine diphosphate ribose exhibited weaker ABA-stimul

223 is a calcium-permeable channel activated by adenosine diphosphate ribose metabolites and oxidative s

224 accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase (PARP) cleavage

225 age during transplantation can activate poly-adenosine diphosphate ribose polymerase (PARP) resulting

226 ial growth factor, 3-nitrotyrosine, and poly(adenosine diphosphate ribose) expression in lung tissue.

227 NBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

228 Methods: We used a radiolabled poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

229 wn or putative radiosensitizers such as poly(adenosine diphosphate ribose) polymerase and mammalian-t

230 ired IHHs displayed caspase activation, poly(adenosine diphosphate ribose) polymerase cleavage, and a

231 In cells deficient in the telomeric poly(adenosine diphosphate ribose) polymerase tankyrase 1, si

232 entification of an unexpected molecule, poly(adenosine diphosphate ribose), that may be implicated in

233 ATR), DNA-dependent protein kinase, and poly[adenosine diphosphate ribose] polymerase (PARP) 1/2.

234 on stress, a defect accentuated by poly-ADP (adenosine diphosphate) ribose polymerase inhibitors.

235 Similarly, the NAD-dependent poly(adenosine diphosphate)ribose polymerase 1 (PARP1) may af

236 ) resulting in the generation of polymers of adenosine diphosphate-ribose (PAR).

237 PM2 channels were activated by intracellular adenosine diphosphate-ribose and blocked by flufenamic a

238 rial dysfunction, caspase cleavage, and poly adenosine diphosphate-ribose polymerase (PARP) degradati

239 Poly-adenosine diphosphate-ribose polymerases (PARPs) promote

240 ROS), 3-nitrotyrosine (marker of RNS), poly(adenosine diphosphate-ribose) (PAR, marker of PARP activ

241 noblots demonstrated adaphostin induced poly(adenosine diphosphate-ribose) polymerase (PARP) cleavage

242 ected by caspases-3 and -8 cleavage and poly(adenosine diphosphate-ribose) polymerase (PARP) degradat

243 repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

244 a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

245 ient epithelial ovarian cancer (EOC) to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

246 f caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).

247 gen species (RNS) and the activation of poly(adenosine diphosphate-ribose) polymerase (PARP).

248 the human bax promoter and found that poly (adenosine diphosphate-ribose) polymerase 1 recruited the

249 mitochondrial membrane potential, and poly (adenosine diphosphate-ribose) polymerase cleavage.

250 C-alpha, phospho-PKC-beta1, and cleaved poly(adenosine diphosphate-ribose) polymerase in post-CP/Rep

251 HR) as measured by hypersensitivity to poly (adenosine diphosphate-ribose) polymerase inhibition and

252 high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor 3-ami

253 e II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olapa

254 nstability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, com

255 cyclin-dependent kinase inhibitors and poly(adenosine diphosphate-ribose) polymerase inhibitors.

256 ospho-PKC-alpha, phospho-PKC-beta1, and poly(adenosine diphosphate-ribose) polymerase were quantified

257 actor, caspase 3, caspase 8, caspase 9, poly(adenosine diphosphate-ribose) polymerase, B-cell lymphom

258 Subsequent to the break, poly(adenosine diphosphate-ribose) polymerase-1 enzymatic act

259 activity of caspase-3/7 and cleavage of poly(adenosine diphosphate-ribose) polymerase.

260 r 1) prevents it from inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DN

261 an essential substrate for sirtuins and poly(adenosine diphosphate-ribose) polymerases (PARPs), which

262 other enzymes such as the sirtuins and poly(adenosine diphosphate-ribose) polymerases.

263 luorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expressio

264 The poly(adenosine diphosphate-ribose)polymerase (PARP) family of

265 ), enhanced cell death (caspase 3/7 and poly[adenosine diphosphate-ribose] polymerase activity, chrom

266 of PARPi-FL, a fluorescent inhibitor of poly[adenosine diphosphate-ribose]polymerase 1 (PARP1), which

267 by caspase-8, -9, and -3 and PARP (poly-ADP [adenosine diphosphate]-ribose polymerase) cleavage and d

268 A allele contributed to significantly lower adenosine diphosphate ribosyl transferase (ADPRT)/PARP-1

269 to rifampin, and harbored arr-3, a rifampin adenosine diphosphate-ribosyl transferase.

270 the synthesis and distribution of the unique adenosine diphosphate-ribosylating and vacuolating Commu

271 ng to multiple low-affinity sites comprising adenosine diphosphate ribosylation factor 1 (Arf-1)-guan

272 interacts with and regulates the activity of adenosine diphosphate ribosylation factor 6 (ARF6), a sm

273 lized guanine nucleotide exchange factor for adenosine diphosphate ribosylation factor GTPases.

274 Furthermore, we identified the adenosine diphosphate ribosylation factor-1 GTPase to be

275 idopsis thaliana AGD1 gene encodes a class 1 adenosine diphosphate ribosylation factor-gtpase-activat

276 the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor-like protein 1

277 lyl cyclase (AC) in response to CT is due to adenosine diphosphate ribosylation of the small G protei

278 ompared with the wild-type immunotoxin in an adenosine diphosphate-ribosylation assay.

279 ation of p47phox, PLD-containing organelles, adenosine diphosphate-ribosylation factor 1, RhoA, prote

280 ads to activation of the Rac1 GTPase through adenosine diphosphate-ribosylation factor 6 (Arf6).

281 The antigen representing adenosine diphosphate-ribosylation factor GTPase activat

282 Adenosine diphosphate ribosyltransferases (ARTDs; ARTD1-

283 ship between oxygen consumption (baseline or adenosine diphosphate stimulated) and human leukocyte an

284 tains an RGD motif and binds equally well to adenosine diphosphate-stimulated human and rodent platel

285 Adenosine diphosphate-stimulated mitochondrial respirati

286 In vitro, L5 enhanced adenosine diphosphate-stimulated platelet aggregation tw

287 Cs (p < .01), with an attenuated response to adenosine diphosphate stimulation (p < .01).

288 ative phosphorylation was investigated using adenosine diphosphate stimulation.

289 tion, and they responded to stimulation with adenosine diphosphate, thrombin, and the PAR4 thrombin r

290 drolysis of adenosine triphosphate (ATP) and adenosine diphosphate to adenosine monophosphate on NK c

291 d upon the enzymatic transphosphorylation of adenosine diphosphate to adenosine triphosphate was used

292 ed by a rotary ATP synthase to phosphorylate adenosine diphosphate to ATP.

293 From adenosine diphosphate to oxygen ratio measurements on pr

294 Application of exogenous adenosine diphosphate to silenced GS52 roots restored no

295 iphosphate synthases, adenosine triphosphate/adenosine diphosphate translocase, and catalase (all p <

296 light transmittance aggregometry with 5 muM adenosine diphosphate, VerifyNow P2Y(12), and vasodilato

297 as the P2Y1-specific agonist 2-methylthio-5'-adenosine diphosphate was, again, only effective in a sm

298 r glycoprotein VI agonists, but responses to adenosine diphosphate were impaired.

299 phosphates (e.g., adenosine triphosphate and adenosine diphosphate) were readily degraded into a mono

300 switch I suggest a role for it in "ejecting" adenosine diphosphate when kinesin initially binds to th